دورية أكاديمية
Neutrophil-activating therapy for the treatment of cancer.
| العنوان: | Neutrophil-activating therapy for the treatment of cancer. |
|---|---|
| المؤلفون: | Linde IL; Program in Immunology, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Prestwood TR; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Qiu J; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Pilarowski G; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Linde MH; Program in Immunology, Stanford University, Stanford, CA 94305, USA., Zhang X; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Shen L; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Reticker-Flynn NE; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Chiu DK; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Sheu LY; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Van Deursen S; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Tolentino LL; Department of Pathology, Stanford University, Stanford, CA 94305, USA., Song WC; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Engleman EG; Program in Immunology, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University, Stanford, CA 94305, USA. Electronic address: edengleman@stanford.edu. |
| المصدر: | Cancer cell [Cancer Cell] 2023 Feb 13; Vol. 41 (2), pp. 356-372.e10. Date of Electronic Publication: 2023 Jan 26. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge, Mass. : Cell Press, c2002- |
| مواضيع طبية MeSH: | Neoplasms*/drug therapy , Neoplasms*/metabolism , Antineoplastic Agents*, Mice ; Animals ; Humans ; Neutrophils ; Leukotriene B4/metabolism ; Leukotriene B4/pharmacology ; Tumor Necrosis Factor-alpha/metabolism |
| مستخلص: | Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents. Here, we demonstrate in mouse models that neutrophils can be harnessed to induce eradication of tumors and reduce metastatic seeding through the combined actions of tumor necrosis factor, CD40 agonist, and tumor-binding antibody. The same combination activates human neutrophils in vitro, enabling their lysis of human tumor cells. Mechanistically, this therapy induces rapid mobilization and tumor infiltration of neutrophils along with complement activation in tumors. Complement component C5a activates neutrophils to produce leukotriene B Competing Interests: Declaration of interests I.L.L., T.R.P., and E.G.E. are co-inventors on a patent application filed by Stanford University related to this work. W.-C.S. owns equity in, receives a consultant fee and research grant from, and is an inventor of patents licensed to Kira Pharmaceuticals and Aevitas Therapeutics. The other authors declare no competing interests. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| التعليقات: | Comment in: Cancer Cell. 2023 Feb 13;41(2):227-229. (PMID: 36787693) Comment in: Nat Rev Cancer. 2023 Apr;23(4):190. (PMID: 36864183) |
| References: | Cells. 2021 Jun 15;10(6):. (PMID: 34203915) Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. (PMID: 29949776) J Immunol. 2008 Oct 15;181(8):5791-802. (PMID: 18832739) Cell Host Microbe. 2018 Jan 10;23(1):121-133.e4. (PMID: 29290576) J Vis Exp. 2016 Aug 14;(114):. (PMID: 27584043) Int J Cancer. 2014 Sep 1;135(5):1178-86. (PMID: 24501019) Cancer Discov. 2017 Jul;7(7):694-703. (PMID: 28288993) Cell. 2017 Jan 26;168(3):487-502.e15. (PMID: 28111070) Int J Cancer. 2019 Jan 1;144(1):136-149. (PMID: 30121947) Glycobiology. 2020 Mar 20;30(4):254-267. (PMID: 31616919) Carcinogenesis. 2018 Feb 9;39(2):272-282. (PMID: 29228136) Front Cell Infect Microbiol. 2017 May 29;7:217. (PMID: 28611952) J Clin Invest. 2014 Dec;124(12):5466-80. (PMID: 25384214) Nature. 2019 May;569(7754):73-78. (PMID: 30996346) Cancer Immunol Res. 2018 Oct;6(10):1186-1198. (PMID: 30108045) Cancer Cell. 2016 Jun 13;29(6):832-845. (PMID: 27265504) Immunity. 2018 Apr 17;48(4):716-729.e8. (PMID: 29625895) Nature. 2009 May 14;459(7244):262-5. (PMID: 19329995) J Exp Med. 2021 Apr 5;218(4):. (PMID: 33566112) Blood. 2012 Oct 25;120(17):3444-54. (PMID: 22936657) J Immunol. 2013 Apr 1;190(7):3552-9. (PMID: 23427256) Cell. 2019 Apr 18;177(3):541-555.e17. (PMID: 30955887) Immunology. 1996 Sep;89(1):105-11. (PMID: 8911147) J Immunol. 2012 Nov 1;189(9):4674-83. (PMID: 23028051) Blood. 2016 Feb 18;127(7):898-907. (PMID: 26647392) Nat Biotechnol. 2016 Feb;34(2):184-191. (PMID: 26780180) Blood. 2006 Oct 1;108(7):2455-62. (PMID: 16772606) Biochim Biophys Acta. 2013 Mar;1833(3):680-5. (PMID: 23228566) Cancer Res. 2001 Jun 15;61(12):4756-60. (PMID: 11406548) Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3177-85. (PMID: 23112187) Nat Med. 2015 Aug;21(8):938-945. (PMID: 26193342) Cancer Res. 2014 Jul 1;74(13):3454-65. (PMID: 24786787) Nat Rev Cancer. 2020 Sep;20(9):485-503. (PMID: 32694624) J Exp Med. 1975 Jun 1;141(6):1442-7. (PMID: 165258) Nat Rev Immunol. 2021 Aug;21(8):485-498. (PMID: 33526920) Nature. 2013 Jun 20;498(7454):371-5. (PMID: 23708969) Cancer Cell. 2016 Jul 11;30(1):120-135. (PMID: 27374224) J Exp Med. 1995 Jan 1;181(1):435-40. (PMID: 7807024) J Clin Invest. 2010 Oct;120(10):3545-54. (PMID: 20941861) Nat Immunol. 2008 Nov;9(11):1225-35. (PMID: 18820683) Blood. 2013 Oct 31;122(18):3160-4. (PMID: 23980063) Cancer Med. 2016 Mar;5(3):546-57. (PMID: 26687331) Cancer Immunol Immunother. 2020 Jun;69(6):1113-1130. (PMID: 32114681) Nature. 2019 Feb;566(7745):553-557. (PMID: 30728496) Cell Res. 2010 Jan;20(1):34-50. (PMID: 20010915) J Clin Invest. 1996 Jun 1;97(11):2680-4. (PMID: 8647963) Cell Rep. 2015 Feb 3;10(4):562-73. (PMID: 25620698) Immunity. 2020 Aug 18;53(2):303-318.e5. (PMID: 32579887) Oncoimmunology. 2015 Aug 12;5(1):e1067744. (PMID: 26942086) Nature. 2015 Jun 18;522(7556):345-348. (PMID: 25822788) Immunity. 2018 Feb 20;48(2):364-379.e8. (PMID: 29466759) Cancer Cell. 2015 Dec 14;28(6):785-799. (PMID: 26678340) J Biol Chem. 2015 Apr 24;290(17):10667-76. (PMID: 25739439) Cell. 2019 Jul 11;178(2):346-360.e24. (PMID: 31257026) Nature. 2015 Dec 17;528(7582):413-7. (PMID: 26649828) Am J Hematol. 2015 Dec;90(12):1155-8. (PMID: 26347989) Cancer Cell. 2009 Sep 8;16(3):183-94. (PMID: 19732719) Front Immunol. 2019 Feb 08;10:168. (PMID: 30800125) Nat Rev Immunol. 2011 Jul 25;11(8):519-31. (PMID: 21785456) Nat Rev Cancer. 2019 Dec;19(12):698-715. (PMID: 31666715) Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8. (PMID: 16891410) Blood. 2011 Jan 27;117(4):1340-9. (PMID: 21063021) J Exp Med. 2006 Apr 17;203(4):829-35. (PMID: 16567386) J Clin Invest. 2010 Apr;120(4):1151-64. (PMID: 20237412) Oncotarget. 2011 Oct;2(10):739-51. (PMID: 22036896) Science. 2017 Dec 1;358(6367):. (PMID: 29191879) Cancer Cell. 2011 Sep 13;20(3):300-14. (PMID: 21907922) Int J Cancer. 2019 Oct 15;145(8):2267-2281. (PMID: 30860605) Nat Rev Clin Oncol. 2019 Oct;16(10):601-620. (PMID: 31160735) J Immunol. 2004 Jan 15;172(2):989-99. (PMID: 14707072) Kidney Int. 2019 Jul;96(1):67-79. (PMID: 30910380) Mol Immunol. 2019 Oct;114:629-642. (PMID: 31542608) Cell. 2012 Jul 6;150(1):165-78. (PMID: 22770218) Nature. 2015 May 7;521(7550):99-104. (PMID: 25924063) Nat Protoc. 2013 Nov;8(11):2281-2308. (PMID: 24157548) J Immunol Methods. 1991 Feb 15;136(2):287-94. (PMID: 1999656) Cytometry A. 2009 Jan;75(1):14-24. (PMID: 19023891) Nat Commun. 2015 Apr 29;6:7064. (PMID: 25923988) Semin Immunol. 2017 Oct;33:37-43. (PMID: 29042027) Nat Rev Cancer. 2016 Jul;16(7):431-46. (PMID: 27282249) Front Pharmacol. 2020 Aug 19;11:1289. (PMID: 32973519) |
| معلومات مُعتمدة: | R01 AI117410 United States AI NIAID NIH HHS; F31 CA196029 United States CA NCI NIH HHS; R01 CA233958 United States CA NCI NIH HHS; R01 AI146162 United States AI NIAID NIH HHS; R01 AI085596 United States AI NIAID NIH HHS; U54 CA209971 United States CA NCI NIH HHS; R01 CA262361 United States CA NCI NIH HHS; F32 CA189408 United States CA NCI NIH HHS; R01 CA222969 United States CA NCI NIH HHS; T32 HL120824 United States HL NHLBI NIH HHS; R01 CA251174 United States CA NCI NIH HHS; P01 CA244114 United States CA NCI NIH HHS; F30 CA196145 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: C5a; CD40; cancer immunotherapy; complement; leukotriene B4; neutrophil; reactive oxygen species; tumor immunology; tumor necrosis factor; xanthine oxidase |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 1HGW4DR56D (Leukotriene B4) 0 (Tumor Necrosis Factor-alpha) |
| تواريخ الأحداث: | Date Created: 20230127 Date Completed: 20230216 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| مُعرف محوري في PubMed: | PMC9968410 |
| DOI: | 10.1016/j.ccell.2023.01.002 |
| PMID: | 36706760 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1878-3686 |
|---|---|
| DOI: | 10.1016/j.ccell.2023.01.002 |